

Freedom of Information Request: 0032 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Queen Elizabeth Hospital Birmingham

Please detail the number of Oncology patients treated¹ (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months January 2018 to December 2018 inclusive.

The Trust does hold this information, however, to provide it would require manual review of both paper and electronic patient records. We estimate this would take in excess of 18 hours. We are therefore withholding this information under section 12 of the Freedom of Information Act.

We have provided the total number of packs issued from our pharmacy.

		Total Number of Patients Treated:					
		Total Number of Patients Treated (regardless of Tumour Type) (Total Unit issued)	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)		792					
Nivolumab (Opdivo)		1467					
Ipilimumab (Yervoy)		415					
Nivolumab & Ipilimumab	Nivolumab	694					
	Ipilimumab	494					
Dabrafenib (Tafinlar)		37464					
Cabozantinib (Cabometyx)		4710					
Sunitinib (Sutent)		4641					
Pazopanib (Votrient)		17373					
Axitinib (Inlyta)		5865					
Atezolizumab (Tecentriq)		59					

¹ Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).

Sorafenib (Nexavar)	19687					
Tivozanib (Fotivda)	42					
Cetuximab (Erbix)	1077					
Everolimus (Afinitor)	5123					
Vemurafenib (Zelboraf)	112					
Total Number Treated (all treatments)	100015					

Heartlands, Good Hope and Solihull Hospital

Please detail the number of Oncology patients treated² (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months January 2018 to December 2018 inclusive.

We do not record diagnosis information on our prescribing system. We have provided the number of patients who have received each listed treatment.

	Total Number of Patients Treated:					
	Total Number of Patients Treated (regardless of Tumour Type)	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	45					
Nivolumab (Opdivo)	22					
Ipilimumab (Yervoy)						
Nivolumab & Ipilimumab						
Dabrafenib (Tafinlar)						
Cabozantinib (Cabometyx)	7					
Sunitinib (Sutent)	7					
Pazopanib (Votrient)	27					
Axitinib (Inlyta)						
Atezolizumab (Tecentriq)	7					
Sorafenib (Nexavar)	8					
Tivozanib (Fotivda)	1					
Cetuximab (Erbix)	46					
Everolimus (Afinitor)	6					

² Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).

Vemurafenib (Zelboraf)						
Total Number Treated (all treatments)	176					